Year: 2010
Type: article
Abstract: It has been a decade since the regulatory approval of temozolomide, the first drug specifically developed for the treatment of malignant glioma. Initially, only a conditional approval was granted b...
DOI: 10.1586/era.10.161
Authors: Roger Stupp, Monika Hegi, Michael Weller
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: Pfizer
OpenAlex ID: W1997302107
